Abbott’s Xience family of stents received U.S. Food and Drug Administration approval for one-month (as short as 28 days) dual anti-platelet therapy labeling for high bleeding risk patients in the United States.
The U.S. FDA’s Circulatory System Devices Panel is undergoing two days of presentations and meetings regarding mortality rates associated with the use of paclitaxel-coated balloons and paclitaxel-eluting stents.
The U.S. Food and Drug Administration approved Boston Scientific Corp.’s drug-coated stent Eluvia to treat narrowed arteries in the leg.
Novartis’ eye care unit Alcon is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye, but the Swiss drugmaker said the move would not affect plans to spin off the unit 2019.
Boston Scientific Corp. forked over up to $160 million to acquire California stent maker Veniti Inc. The deal marks the third acquisition for Boston Scientific in two months.
Abbott received approval from the U.S. Food and Drug Administration for XIENCE Sierra, the newest generation of the gold-standard XIENCE everolimus-eluting coronary stent system.
U.S. health regulators said they approved a stent by Abbott Laboratories that is the first designed to be absorbed into the bloodstream after it is implanted.
U.S. government scientists have raised questions about the potential risks to patients of heart attacks and blood clots from Abbott Laboratories’ novel coronary stent that dissolves after it is implanted. […]
A novel dissolving heart stent developed by Abbott Laboratories proved comparably safe and effective as its market-leading Xience stent in a large, late-stage trial that will be used to seek […]
